Cardiovascular Drugs market Report from The Delvens highlights on deep analysis of market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, Key Competitors market shares, and strategies that are key to the Global market. These Cardiovascular Drugs market insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions.
The Cardiovascular Drugs market size was estimated at USD 168.36 billion in 2023 and is projected to reach USD 221.85 billion in 2030 at a CAGR of 4.02% during the forecast period 2023-2030.
Get Free Sample Report@ https://www.delvens.com/get-free-sample/cardiovascular-drugs-market
Cardiovascular drugs are medications that are used to treat various conditions related to the heart and blood vessels. They are prescribed to manage heart diseases and other cardiovascular disorders. Cardiovascular medicines are often used in combination to treat different aspects of a cardiovascular disease. There are various types of cardiovascular drugs such as antihypertensives that are used to lower blood pressure, anticoagulants that are used to prevent blood clots, antihyperlipidemic that are used to lower cholesterol and triglyceride levels, antiarrhythmics that are used to regulate abnormal heart rhythms. Most cardiovascular drugs are prescribed to treat hypertension and dyslipidaemia which are majorly responsible for the formation of atherosclerotic plaque within blood vessels restricting blood flow to the body parts resulting in multiple cardiac indications such as stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis.
Competitive Landscape: Cardiovascular Drugs market
• Amgen Inc
• Baxter
• Bayer AG
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Johnson & Johnson
• Lupin
• Merck & Co., Inc. (MSD)
• Novartis AG
• Pfizer Inc.
• Sanofi S A
• Bristol-Myers Squibb Company
• AstraZeneca
• Janssen Pharmaceuticals, Inc.
• Daiichi Sankyo
• Portola Pharmaceuticals
• United Therapeutics Corp
For More Inquiry Contact us@ https://www.delvens.com/Inquire-before-buying/cardiovascular-drugs-market
Key Findings:
• Based on drug class the market can be segmented into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others.
• Based on indication, the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. The hypertension segment dominated the market in this segment and garnered the highest share.

• On the basis of distribution channel, the market can be segmented into hospitals, pharmacies and others. The hospitals segment dominated the market in this segment which can be attributed to the high demand for cardiovascular drugs in the hospital.
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period.
Recent Developments
• In May 2022, Amgen revealed positive data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events.
• In February 2022, the Food and Drug Administration (FDA) expanded its approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization. The medication was approved in August 2021 to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction (HFrEF).
Reasons to Acquire
• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Cardiovascular Drugs Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Access Full Report@ https://www.delvens.com/report/cardiovascular-drugs-market
In addition to the market data for the Cardiovascular Drugs Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
Browse More Reports from Delvens:
Assisted Living (AL) market size was estimated at USD 180.70 billion in 2023 and is projected to reach USD 305.70 billion in 2030 at a CAGR of 7.8% during the forecast period 2023-2030.
Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.
Periodontal Disease Treatment market size was estimated at USD 799.17 million in 2023 and is projected to reach USD 1438.54 million in 2030 at a CAGR of 8.76% during the forecast period 2023-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
[email protected]